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Abstract 
Background: We report for the first time a case of community acquired Chryseobacterium indologenes soft tissue 
infection in an immunocompetent patient.
Case presentation: A 11 year female child, from South-Asia of Indian origin presented with fever, pain and swelling 
in right leg for 3 days with no significant past history. Incision and drainage was done and pus was sent for culture 
and sensitivity. Radiological investigation showed subtle irregular soft tissue density. Pus culture grew multidrug 
resistant C. indologenes.
Conclusion: Though of low pathogenicity, our case emphasises its unpredictable nature and the need to determine 
minimum inhibitory concentration breakpoints for therapy.
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Background
Previously known as Flavobacterium, the genus Chry-
seobacterium comprising six species are non-glucose 
fermenting bacilli. Chryseobacterium indologenes spe-
cies was first isolated in 1993 from tracheal aspirate of 
a patient complicated with ventilator associated pneu-
monia. The clinical significance of the infections due to 
C. indologenes is poorly studied as not many cases are 
reported in literature and is also a rare human pathogen. 
Commonly seen in the environment, these are known to 
cause a spectrum of infections usually in hospitalized and 
immunocompromised patients, and in infants. Here we 
describe a case of C. indologenes infection in an immuno-
competent child.
Case presentation
A 11  year old female child from South-Asia of Indian 
origin, presented to the orthopaedics department with 
complaints of fever, non-traumatic pain and swelling 
in the right leg for about 3  days. There was no signifi-
cant past history. She was septic and was noted to have 
a diffuse swelling over the upper third of right leg with 
skin erythema, warmth and tenderness. No discharg-
ing sinuses were noted. Blood investigations showed a 
raised white cell count and marginally increased erythro-
cyte sedimentation rate (ESR). Rest of the haematologi-
cal and biochemical markers were within normal limits. 
Blood sample was sent for culture and sensitivity which 
showed no growth. Anteroposterior and lateral views 
of plain radiograph of the right leg showed normal tibia 
and fibula with subtle irregular altered soft tissue density 
in the lateral aspect of the mid third of the leg (Fig.  1). 
Incision and drainage was performed the following day 
under general anaesthesia. Thick purulent discharge was 
drained and about 5 ml of the discharge was sent for cul-
ture and sensitivity. The wound was left open and dressed 
appropriately (Table 1).
Gram staining of the purulent material showed numer-
ous pus cells and gram negative bacilli. Inoculation in 
blood agar showed dark yellow pigmented colonies 
Open Access
BMC Research Notes
*Correspondence:  dr.jmeasow@gmail.com 
1 Department of Microbiology, Sri Venkateshwaraa Medical College 
Hospital and Research Centre, Ariyur, Puducherry 605 102, India
Full list of author information is available at the end of the article
Page 2 of 5Srinivasan et al. BMC Res Notes  (2016) 9:212 
with no hemolysis (Fig. 2). On nutrient agar yellow pig-
mented colonies were seen and were noticed to turn to 
red when 10  % potassium hydroxide (KOH) was added 
on to the culture (Fig.  3). It did not grow in Mac Con-
key agar. The isolate was non-motile, catalase and oxidase 
positive, indole positive, methyl red negative and Voges–
Proskauer’s negative. Urea was not hydrolysed and citrate 
was not utilized. On triple sugar iron agar, glucose was 
utilised with gas production. The organism was identified 
by both conventional method and VITEK-2 systems ver-
sion: 07.01 as C. indologenes.
Genus was presumptively identified as Chryseobac-
terium after 24 h and genus confirmation, species iden-
tification and sensitivity results were available in 48  h. 
The minimum inhibitory concentration (MIC) values by 
VITEK-2 system are in Table 2.
Our isolate was susceptible to imipenem and resist-
ant to meropenem and doripenem. Chryseobacterium 
species are intrinsically resistant to most beta lactams 
including carbapenems due to the production of chromo-
somally mediated metallobetalactamases (MBL). The iso-
late was a MBL producer which was confirmed by double 
disk diffusion method with ethylene diamine tetraacetic 
acid (EDTA).
Patient was empirically started on parenteral cefotax-
ime, metronidazole and gentamicin, was changed over 
to intravenous ceftazidime 1 g twice daily and metroni-
dazole infusion 500 mg thrice daily for 5 days based on 
the sensitivity report following which significant clinical 
improvement was noted. Subsequently secondary closure 
was done 10  days later. The wound healed well and the 
patient was discharged on oral antibiotics with follow up. 
Consent for publication was obtained from the patient’s 
parent.
Discussion
Infection due to C. indologenes in humans is a rare occur-
rence and is usually nosocomial. These are mainly found 
in soil, plants, water and foodstuffs. They are not found in 
Fig. 1 Plain radiograph anteroposterior projection demonstrating 
patchy irregular increased soft tissue densities in the lateral aspect of 
the middle third of the right leg as marked by the arrow
Table 1 Timeline of case management
Time Process followed Observation and management
Day 1 History Fever, pain and swelling for 3 days
Physical examination Swelling with erythema, warmth and tenderness
Blood count, erythrocyte sedimentation rate Raised white cell count
Marginally elevated erythrocyte sedimentation rate
X-ray Normal tibia and fibula with subtle irregular altered soft tissue density in the lateral 
aspect of the mid-third of the leg
Blood culture No growth after 7 days of incubation
Treatment Patient was empirically given parenteral cefotaxime, metronidazole and gentamicin
Day 2 Incision and drainage under general anaesthesia Thick purulent discharge was obtained and sent for culture and sensitivity
Gram stain Plenty of pus cells and gram negative bacilli were seen
Culture On incubation
Day 3 Genus identification by conventional method Chryseobacterium spp.
Subjected for VITEK-2 identification and antibiotic sensitivity testing
Day 4 Species identification by conventional and VITEK-2 C. indologenes
Minimum inhibitory concentration values by VITEK-2 as in Table 2
Day 5 Switching of antibiotics Cefotaxime was changed over to ceftazidime
Gentamicin was discontinued
Day 5–12 Local examination Wound was healing well, secondary closure done and patient was discharged
Page 3 of 5Srinivasan et al. BMC Res Notes  (2016) 9:212 
human flora. Within the hospital premises, they exist in 
water systems and wet surfaces and can survive in chlo-
rinated water [1].
Chryseobacterium species are gram-negative, aerobic, 
non-motile, oxidase positive, catalase positive, indole 
positive, producing a distinct yellow orange pigment 
due to production of flexirubin. Indole was produced in 
tryptophan broth. The genus Chryseobacterium belongs 
to the family Flavobacteriaceae. The commonly isolated 
species includes C. meningosepticum, C. multivorum, C. 
odoratum, C. breve and group IIb Chryseobacterium spe-
cies which includes C. indologenes and C. gleum. Of these 
C. meningosepticum is the most pathogenic causing neo-
natal meningitis [2].
Chryseobacterium infections are frequently associ-
ated with the presence of indwelling devices like intra-
vascular catheters etc., in immunocompromised patients 
or in patients on long-term broad-spectrum antibi-
otics. Factors influencing the development of Chry-
seobacterium infection include a suitable entry port, 
invasive procedures, neutropenia, production of bio-
film on foreign materials, prolonged use of antibiotics 
and immunodeficiency [3, 4]. Infections associated with 
Chryseobacterium species include bacteremia, wound 
sepsis, indwelling device associated infections, ocular 
infections and intra-abdominal infections. In our patient 
it was associated with cellulitis, soft tissue infection and 
abscess formation. They are usually isolated from clinical 
specimens but rarely from blood as were in our case [4].
Most of the C. indologenes infections described in lit-
erature were hospital acquired and were seen in patients 
with underlying debilitating diseases [4–9]. Mostly 
our isolate is community acquired, as the sample grew 
Chryseobacterium from pus collected intraoperatively 
on the second day of admission. During the above said 
period, environmental surveillance samples did not grow 
Chryseobacterium.
Interestingly our patient was not immunosuppressed 
or was on any long term antibiotics or with indwell-
ing devices, making this case unusual in presentation. 
Douvoyiannis et al. [10] had reported the first case of C. 
indologenes in a 33 day old infant in 2010. Hendaus et al. 
[11] reported the second case of C. indologenes infection 
from healthy newborn in 2013. Ours would be the third 
case of C. indologenes infection reported from an immu-
nocompetent paediatric patient.
Not much data is available in literature on the choice 
of appropriate antibiotic for empirical treatment in C. 
indologenes infections [12]. This uncertainty is attributed 
to the wide spectrum of antimicrobial resistance, lack of 
gold standard susceptibility testing, unpredictable nature 
and non-establishment of MIC breakpoints for these 
organisms [13]. Further, biofilm and proteases produc-
tion by C. indologenes species reduces its antimicrobial 
susceptibility [14]. Based on the results of SENTRY anti-
microbial surveillance program during 1997–2001, the 
highest prevalence of Chryseobacterium was seen among 
the elderly. The most appropriate antibiotics that can be 
used for treating Chryseobacterium infections are newer 
fluoroquinolones (MIC 90–1 µg/ml) followed by rifampin 
(MIC 90–2  µg/ml). C. indologenes isolates showed ade-
quate susceptibilities to trimethoprim-sulfamethoxazole, 
ciprofloxacin and piperacillin–tazobactam [15]. Variable 
Fig. 2 Blood agar showing non-haemolytic yellow pigmented colo-
nies of C. indologenes
Fig. 3 Yellow pigmented colonies of C. indologenes turning to red 
upon addition of 10 % potassium hydroxide
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susceptibility to vancomycin has been reported in litera-
ture [16].
Chryseobacterium indologenes is invariably resistant to 
aminoglycosides, shows varying degree of resistance to 
carbapenems, cephalosporins, piperacillin–tazobactam 
and are susceptible to fluroquinolones and cotrimoxa-
zole. Based on the sensitivity pattern reported in SEN-
TRY [15] and other literatures [9, 10, 17], there was no 
evident difference for community acquired isolates as 
compared with hospital acquired strains.
In this study, the isolate was resistant to meropenem 
and susceptible to imipenem by VITEK-2 systems. This 
could be due to different mechanisms involved in imipe-
nem and meropenem resistance. Meropenem resistance 
is due to efflux systems and imipenem resistance is by 
porin mutations. Over expression of MexAB-OprM, an 
efflux system pumps out meropenem but not imipenem 
[18]. As the isolate was confirmed to be a MBL producer 
by imipenem-EDTA double disc diffusion test, all the 
carbapenems were reported as resistant for therapeutic 
purpose.
Disk diffusion methods are not reliable and thus sus-
ceptibility testing by broth micro dilution method should 
be performed [19].
Conclusion
Listed as one of the nosocominal infections, C. indolo-
genes infections known for its rare and sporadic inci-
dence can cause potentially serious infections in humans. 
As described they can cause significant infections in 
immunocompetent individuals as well. More extensive 
and long term studies are required to understand the 
demographics, pathogenicity, virulence factors, arbitrary 
antimicrobial resistance and appropriate antimicrobial 
therapy.
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